FDA Approves Nivolumab with Chemotherapy for Previously Untreated Hodgkin Lymphoma By Ogkologos - April 1, 2026 67 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the Study CA209-8UT (SWOG 1826) Source RELATED ARTICLESMORE FROM AUTHOR Low-Dose Pembrolizumab with Dose-Dense Chemotherapy Increases pCR as Neoadjuvant Treatment for Localised TNBC ESMO Advocates for Equal Access to Optimal Cancer Care for all Patients with Cancer at the 79th World Health Assembly Daraxonrasib Shows Antitumour Activity Among Patients with Previously Treated RAS-mutated Pancreatic Ductal Adenocarcinoma MOST POPULAR Gut Microbes May Influence How Well Radiation Therapy Works against Cancer September 2, 2021 Navigating the Challenges of Gynecologic Cancer Survivorship: An Expert Perspective May 10, 2022 Disguising Cancer as an Infection Helps the Immune System Eliminate Tumors July 22, 2022 Cancer Research UK releases 2022 gender and ethnicity pay gap reports March 23, 2023 Load more HOT NEWS Touching a nerve: How neuroscience could advance our understanding of cancer Tumour Budding Demonstrates Independent Prognostic Value for Disease-Free and Overall Survival... Risk of Distant Recurrence of ER-Positive Breast Cancer in Premenopausal Women... Pembrolizumab Demonstrates Robust, Durable Antitumour Activity and Promising Survival in Advanced...
